DPP9 Antibody (OTI2E3)

Western Blot: DPP9 Antibody (OTI2E3) [NBP2-01521]

Western Blot: DPP9 Antibody (2E3) [NBP2-01521] - HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY DPP9 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-DPP9.

Immunohistochemistry-Paraffin: DPP9 Antibody (OTI2E3) [NBP2-01521]

Immunohistochemistry-Paraffin: DPP9 Antibody (2E3) [NBP2-01521] - Staining of paraffin-embedded Adenocarcinoma of Human endometrium tissue using anti-DPP9 mouse monoclonal antibody.

Immunohistochemistry-Paraffin: DPP9 Antibody (OTI2E3) [NBP2-01521]

Immunohistochemistry-Paraffin: DPP9 Antibody (2E3) [NBP2-01521] - Staining of paraffin-embedded Adenocarcinoma of Human ovary tissue using anti-DPP9 mouse monoclonal antibody.

Immunohistochemistry-Paraffin: DPP9 Antibody (OTI2E3) [NBP2-01521]

Immunohistochemistry-Paraffin: DPP9 Antibody (2E3) [NBP2-01521] - Staining of paraffin-embedded Carcinoma of Human bladder tissue using anti-DPP9 mouse monoclonal antibody.

Immunohistochemistry-Paraffin: DPP9 Antibody (OTI2E3) [NBP2-01521]

Immunohistochemistry-Paraffin: DPP9 Antibody (2E3) [NBP2-01521] - Staining of paraffin-embedded Carcinoma of Human kidney tissue using anti-DPP9 mouse monoclonal antibody.

Immunohistochemistry-Paraffin: DPP9 Antibody (OTI2E3) [NBP2-01521]

Immunohistochemistry-Paraffin: DPP9 Antibody (2E3) [NBP2-01521] - Staining of paraffin-embedded Carcinoma of Human pancreas tissue using anti-DPP9 mouse monoclonal antibody.

Immunohistochemistry-Paraffin: DPP9 Antibody (OTI2E3) [NBP2-01521]

Immunohistochemistry-Paraffin: DPP9 Antibody (2E3) [NBP2-01521] - Staining of paraffin-embedded Human endometrium tissue using anti-DPP9 mouse monoclonal antibody.

DPP9 Antibody (OTI2E3)[NBP2-01521]

DPP9 Antibody (OTI2E3)[NBP2-01521]Simple Western� analysis of endogenous protein PFKP from MCF-7 lysates (0.1 mg/mL) using PFKP Mouse Monoclonal Antibody. The virtual lane view (left) shows the target (as indicated) at 1:50 dilution of primary antibody. The corresponding electropherogram view (right) plots chemiluminescence by molecular weight along the capillary at a 1:50 dilution of primary antibody. This experiment was performed under reducing conditions on the Jess� Simple Western instrument from ProteinSimple, a Bio-Techne brand, using the 12�230 kDa Separation Module.

Western Blot: DPP9 Antibody (OTI2E3) [NBP2-01521] -

Dependence on HCK for DPP8/9 inhibitor-induced pyroptosis. (A) Expression level of DPP8, DPP9, caspase-1, CARD8, GSDMD, or caspase-3 in THP-1, MM.1S, KARPAS299, KG1, NAMALWA, or Daudi cells was estimated by Western blot analysis. (B) Gene expression of THP-1, MM.1S, KARPAS299, KG1, NAMALWA, or Daudi cells was analyzed by microarray method using 3D-Gene. (C) Expression level of HCK, LCK, Fyn, c-Fgr, Lyn, or Blk in THP-1, MM.1S, KARPAS299, KG1, NAMALWA, or Daudi cells was estimated by Western blot analysis. (D) 1.0 × 105 of hematological cancer cell lines (Jurkat, K562, MOLM-13, NOMO-1, RPMI8226, Raji, or SKM-1) were cultured with 1G244 at doses of 0–10 uM for 72 h. Cell number was estimated by a colorimetric assay using WST-1 reagent (n = 6). (E) Expression level of HCK or CARD8 in Jurkat, K562, MOLM-13, NOMO-1, RPMI8226, Raji, or SKM-1 cells was estimated by Western blot analysis. (F) Knockdown studies of HCK in MM.1S cells. NT, no treatment; GFP, control vector; KD, knockdown. Expression level of HCK was estimated by Western blot analysis. (G) 1.0 × 105 of MM.1S cells and their transfectants were cultured with DPP8/9 inhibitors (1G244 or talabostat) at doses of 0–100 uM for 6 h. Cytotoxicity was estimated by a LDH release assay (n = 6). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37048172), licensed under a CC-BY license. Not internally tested by Novus Biologicals.